“I’m excited to join Adalyon, to leverage the deep expertise of the team and the company’s strong heritage in behavioural science and technology R&D for real impact. Adalyon’s proprietary methodology utilising modern AI/ML capabilities in highly regulated environments stands out as market shaping. We’re pioneering quantified behavioural analytics to modernize clinical research,” says Ulrik Zeuthen, CEO of Adalyon.

Ulrik Zeuthen

Ulrik Zeuthen brings extensive experience from the pharmaceutical and data science sectors, having previously held Director level positions at Novo Nordisk, working in Denmark and Japan, and as a data strategist at Deloitte. He has been responsible for the establishment and execution of partnerships between Novo Nordisk and primary technical partners, to drive the scaled and accelerated AI use case delivery across the company. He holds a Masters of Science (MSc) in Economics from the University of Copenhagen, Denmark.

“I’m looking forward to showcasing the value of our AI-powered Behavioural Intelligence Platform in delivering real-time behavioural and emotional insights for clinical trials and healthcare applications. Specifically, our adaptable ‘patient-centric’ approach is designed as a plug-and-play technology, driving better patient stratification and retention in trials, and with the potential to identify benefits in additional indications, enabling product label extensions and early detection of treatment effects. Our technology has the potential to add tremendous value to pharmaceutical R&D programmes by improving clinical trial outcomes and ultimately delivering more effective drugs and patient outcomes.”

Founder of Adalyon, Katarina Cantell, will transition to the role of Chief Scientific Officer (CSO).